Merck Total Assets from 2010 to 2024

MRK Stock

USD 126.94 1.16 0.92%

Merck Total Assets yearly trend continues to be quite stable with very little volatility. The value of Total Assets are projected to decrease to about 60.3 B. Total Assets is the total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets. View All Fundamentals

Total Assets

First Reported

1985-12-31

Previous Quarter

106.7 B

Current Value

106.7 B

Quarterly Volatility

36.9 B

Black Monday

Oil Shock

Dot-com Bubble

Housing Crash

Credit Downgrade

Yuan Drop

Covid

Check Merck financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Merck main balance sheet or income statement drivers, such as Depreciation And Amortization of 2.8 B, Interest Expense of 1.2 B or Total Revenue of 32.5 B, as well as many exotic indicators such as Price To Sales Ratio of 4.3, Dividend Yield of 0.0246 or PTB Ratio of 6.91. Merck financial statements analysis is a perfect complement when working with Merck Valuation or Volatility modules.

This module can also supplement Merck's financial leverage analysis and stock options assessment as well as various Merck Technical models . Check out the analysis of Merck Correlation against competitors.

Latest Merck's Total Assets Growth Pattern

Below is the plot of the Total Assets of Merck Company over the last few years. Total assets refers to the total amount of Merck assets owned. Assets are items that have some economic value and are expended over time to create a benefit for the owner. These assets are usually recorded in Merck Company books under different categories such as cash, marketable securities, accounts receivable,prepaid expenses, inventory, fixed assets, intangible assets, other assets, marketable securities, accounts receivable, prepaid expenses and others. It is the total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets. Merck's Total Assets historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Merck's overall financial position and show how it may be relating to other accounts over time.

View

Last Reported 106.67 B

10 Years Trend

Pretty Stable

Compare to Others All Fundamentals

Total Assets

Timeline

Merck Total Assets Regression Statistics

	Arithmetic Mean	89,708,787,590
	Geometric Mean	77,760,379,638
	Coefficient Of Variation	29.91
	Mean Deviation	17,123,349,880
	Median	98,335,000,000
	Standard Deviation	26,828,737,977
	Sample Variance	719781181.4T
	Range	104.3B
	R-Value	0.21
	Mean Square Error	742500590.8T
	R-Squared	0.04
	Significance	0.46
	Slope	1,231,185,346
	Total Sum of Squares	10076936540T

Merck Total Assets History

	2024	60.3 B
	2023	106.7 B
	2022	109.2 B
	2021	105.7 B
	2020	91.6 B
	2019	84.4 B
	2018	82.6 B

Other Fundumenentals of Merck Company

Intangibles To Total Assets

Merck Total Assets component correlations

	Total Assets	Total Stockholder Equity	Net Debt	Retained Earnings	Net Receivables	Total Liab	Total Current Assets	Short Term Debt	Intangible Assets	Accounts Payable	Short Term Investments	Capital Stock	Common Stock	Long Term Debt	Good Will	Treasury Stock	Property Plant Equipment	Current Deferred Revenue	Net Tangible Assets	Total Permanent Equity	Long Term Debt Total	Capital Surpluse	Deferred Long Term Liab	Long Term Investments	Accumulated Depreciation	Short Long Term Debt	Cash And Equivalents	Net Invested Capital	Net Working Capital
Total Assets		0.87	0.28	0.88	0.61	0.7	0.98	0.3	0.8	0.49	0.16	0.95	0.95	0.73	0.65	-0.27	0.44	-0.21	-0.22	0.19	0.35	0.22	0.36	0.31	-0.7	0.02	0.19	0.2	0.15
Total Stockholder Equity	0.87		-0.07	0.59	0.43	0.4	0.9	0.08	0.93	0.05	0.37	0.72	0.72	0.36	0.22	0.18	0.21	-0.26	0.23	-0.07	-0.02	0.1	0.61	0.48	-0.48	-0.37	-0.07	0.16	0.35
Net Debt	0.28	-0.07		0.57	0.75	0.83	0.18	0.11	-0.09	0.73	-0.2	0.42	0.42	0.74	0.71	-0.89	0.5	0.52	-0.58	0.54	0.82	0.58	-0.42	-0.26	-0.43	0.32	0.56	0.48	-0.1
Retained Earnings	0.88	0.59	0.57		0.69	0.83	0.84	0.26	0.5	0.8	0.01	0.9	0.9	0.91	0.89	-0.65	0.58	0.03	-0.48	0.37	0.65	0.37	0.04	0.04	-0.74	0.24	0.48	0.37	0.18
Net Receivables	0.61	0.43	0.75	0.69		0.91	0.57	0.13	0.47	0.6	-0.28	0.63	0.63	0.68	0.57	-0.63	0.71	0.5	-0.35	0.51	0.6	0.68	0.08	-0.26	-0.59	0.01	0.58	0.6	0.16
Total Liab	0.7	0.4	0.83	0.83	0.91		0.64	0.35	0.4	0.75	-0.17	0.78	0.78	0.81	0.78	-0.77	0.56	0.25	-0.59	0.52	0.65	0.45	-0.05	-0.09	-0.75	0.28	0.46	0.38	-0.03
Total Current Assets	0.98	0.9	0.18	0.84	0.57	0.64		0.31	0.82	0.4	0.21	0.91	0.91	0.64	0.55	-0.18	0.4	-0.25	-0.12	0.15	0.24	0.18	0.38	0.33	-0.71	-0.06	0.18	0.16	0.19
Short Term Debt	0.3	0.08	0.11	0.26	0.13	0.35	0.31		0.12	0.3	-0.27	0.41	0.41	0.13	0.26	-0.22	0.03	-0.44	-0.47	0.19	-0.13	-0.35	-0.04	0.1	-0.63	0.73	-0.13	-0.43	-0.63
Intangible Assets	0.8	0.93	-0.09	0.5	0.47	0.4	0.82	0.12		0.07	0.15	0.65	0.65	0.29	0.16	0.19	0.28	-0.21	0.14	-0.05	-0.05	0.11	0.75	0.25	-0.47	-0.31	-0.09	0.14	0.22
Accounts Payable	0.49	0.05	0.73	0.8	0.6	0.75	0.4	0.3	0.07		-0.37	0.58	0.58	0.85	0.9	-0.9	0.63	0.25	-0.75	0.44	0.8	0.38	-0.33	-0.39	-0.65	0.57	0.58	0.39	-0.09
Short Term Investments	0.16	0.37	-0.2	0.01	-0.28	-0.17	0.21	-0.27	0.15	-0.37		0.14	0.14	-0.11	-0.14	0.39	-0.55	-0.48	0.36	-0.28	-0.27	-0.35	0.22	0.77	0.11	-0.4	-0.48	-0.3	0.08
Capital Stock	0.95	0.72	0.42	0.9	0.63	0.78	0.91	0.41	0.65	0.58	0.14		1.0	0.77	0.76	-0.42	0.38	-0.27	-0.43	0.3	0.38	0.19	0.24	0.29	-0.7	0.21	0.23	0.06	-0.03
Common Stock	0.95	0.72	0.42	0.9	0.63	0.78	0.91	0.41	0.65	0.58	0.14	1.0		0.77	0.76	-0.42	0.38	-0.27	-0.43	0.3	0.38	0.19	0.24	0.29	-0.7	0.21	0.23	0.06	-0.03
Long Term Debt	0.73	0.36	0.74	0.91	0.68	0.81	0.64	0.13	0.29	0.85	-0.11	0.77	0.77		0.93	-0.76	0.67	0.23	-0.52	0.41	0.88	0.56	-0.2	-0.09	-0.58	0.24	0.6	0.49	0.11
Good Will	0.65	0.22	0.71	0.89	0.57	0.78	0.55	0.26	0.16	0.9	-0.14	0.76	0.76	0.93		-0.83	0.51	0.07	-0.75	0.5	0.79	0.33	-0.2	-0.1	-0.56	0.49	0.51	0.28	-0.02
Treasury Stock	-0.27	0.18	-0.89	-0.65	-0.63	-0.77	-0.18	-0.22	0.19	-0.9	0.39	-0.42	-0.42	-0.76	-0.83		-0.55	-0.44	0.77	-0.56	-0.83	-0.46	0.51	0.43	0.51	-0.54	-0.67	-0.4	0.07
Property Plant Equipment	0.44	0.21	0.5	0.58	0.71	0.56	0.4	0.03	0.28	0.63	-0.55	0.38	0.38	0.67	0.51	-0.55		0.61	-0.23	0.39	0.71	0.84	-0.05	-0.6	-0.41	0.04	0.85	0.75	0.24
Current Deferred Revenue	-0.21	-0.26	0.52	0.03	0.5	0.25	-0.25	-0.44	-0.21	0.25	-0.48	-0.27	-0.27	0.23	0.07	-0.44	0.61		0.07	0.28	0.58	0.81	-0.33	-0.65	0.07	-0.25	0.66	0.85	0.43
Net Tangible Assets	-0.22	0.23	-0.58	-0.48	-0.35	-0.59	-0.12	-0.47	0.14	-0.75	0.36	-0.43	-0.43	-0.52	-0.75	0.77	-0.23	0.07		-0.51	-0.46	0.02	0.23	0.33	0.4	-0.82	-0.31	0.14	0.45
Total Permanent Equity	0.19	-0.07	0.54	0.37	0.51	0.52	0.15	0.19	-0.05	0.44	-0.28	0.3	0.3	0.41	0.5	-0.56	0.39	0.28	-0.51		0.43	0.31	0.0	-0.35	-0.3	0.25	0.41	0.25	-0.04
Long Term Debt Total	0.35	-0.02	0.82	0.65	0.6	0.65	0.24	-0.13	-0.05	0.8	-0.27	0.38	0.38	0.88	0.79	-0.83	0.71	0.58	-0.46	0.43		0.72	-0.42	-0.38	-0.31	0.18	0.74	0.69	0.18
Capital Surpluse	0.22	0.1	0.58	0.37	0.68	0.45	0.18	-0.35	0.11	0.38	-0.35	0.19	0.19	0.56	0.33	-0.46	0.84	0.81	0.02	0.31	0.72		-0.14	-0.47	-0.08	-0.29	0.82	0.84	0.39
Deferred Long Term Liab	0.36	0.61	-0.42	0.04	0.08	-0.05	0.38	-0.04	0.75	-0.33	0.22	0.24	0.24	-0.2	-0.2	0.51	-0.05	-0.33	0.23	0.0	-0.42	-0.14		0.15	0.01	-0.33	-0.33	-0.14	0.08
Long Term Investments	0.31	0.48	-0.26	0.04	-0.26	-0.09	0.33	0.1	0.25	-0.39	0.77	0.29	0.29	-0.09	-0.1	0.43	-0.6	-0.65	0.33	-0.35	-0.38	-0.47	0.15		-0.03	-0.22	-0.6	-0.43	0.01
Accumulated Depreciation	-0.7	-0.48	-0.43	-0.74	-0.59	-0.75	-0.71	-0.63	-0.47	-0.65	0.11	-0.7	-0.7	-0.58	-0.56	0.51	-0.41	0.07	0.4	-0.3	-0.31	-0.08	0.01	-0.03		-0.35	-0.17	-0.15	0.12
Short Long Term Debt	0.02	-0.37	0.32	0.24	0.01	0.28	-0.06	0.73	-0.31	0.57	-0.4	0.21	0.21	0.24	0.49	-0.54	0.04	-0.25	-0.82	0.25	0.18	-0.29	-0.33	-0.22	-0.35		0.07	-0.34	-0.65
Cash And Equivalents	0.19	-0.07	0.56	0.48	0.58	0.46	0.18	-0.13	-0.09	0.58	-0.48	0.23	0.23	0.6	0.51	-0.67	0.85	0.66	-0.31	0.41	0.74	0.82	-0.33	-0.6	-0.17	0.07		0.67	0.34
Net Invested Capital	0.2	0.16	0.48	0.37	0.6	0.38	0.16	-0.43	0.14	0.39	-0.3	0.06	0.06	0.49	0.28	-0.4	0.75	0.85	0.14	0.25	0.69	0.84	-0.14	-0.43	-0.15	-0.34	0.67		0.64
Net Working Capital	0.15	0.35	-0.1	0.18	0.16	-0.03	0.19	-0.63	0.22	-0.09	0.08	-0.03	-0.03	0.11	-0.02	0.07	0.24	0.43	0.45	-0.04	0.18	0.39	0.08	0.01	0.12	-0.65	0.34	0.64

Click cells to compare fundamentals

About Merck Financial Statements

There are typically three primary documents that fall into the category of financial statements. These documents include Merck income statement, its balance sheet, and the statement of cash flows. Merck investors use historical funamental indicators, such as Merck's Total Assets, to determine how well the company is positioned to perform in the future. Although Merck investors may use each financial statement separately, they are all related. The changes in Merck's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Merck's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. We offer a historical overview of the basic patterns found on Merck Financial Statements. Understanding these patterns can help to make the right decision on long term investment in Merck. Please read more on our technical analysis and fundamental analysis pages.

	Last Reported	Projected for Next Year
Total Assets	106.7 B	60.3 B
Intangibles To Total Assets	0.37	0.21

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect

When determining whether Merck Company is a good investment, qualitative aspects like company management, corporate governance, and ethical practices play a significant role. A comparison with peer companies also provides context and helps to understand if Merck Stock is undervalued or overvalued. This multi-faceted approach, blending both quantitative and qualitative analysis, forms a solid foundation for making an informed investment decision about Merck Company Stock. Highlighted below are key reports to facilitate an investment decision about Merck Company Stock:

How To Invest In Merck

Details

Is Merck Stock a good investment?

Details

What is Merck's Net Worth?

Details

Largest Pharmaceuticals Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out the analysis of Merck Correlation against competitors.

You can also try the Financial Widgets module to easily integrated Macroaxis content with over 30 different plug-and-play financial widgets.

Complementary Tools for Merck Stock analysis

When running Merck's price analysis, check to measure Merck's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Merck is operating at the current time. Most of Merck's value examination focuses on studying past and present price action to predict the probability of Merck's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Merck's price. Additionally, you may evaluate how the addition of Merck to your portfolios can decrease your overall portfolio volatility.

	Insider Screener Find insiders across different sectors to evaluate their impact on performance
	Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins
	Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges
	Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios.
	Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios
	Performance Analysis Check effects of mean-variance optimization against your current asset allocation
	Technical Analysis Check basic technical indicators and analysis based on most latest market data
	Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency
	Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes
	Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance

Is Merck's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Merck. If investors know Merck will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Merck listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Quarterly Earnings Growth

0.453

Dividend Share

2.92

Earnings Share

0.14

Revenue Per Share

23.695

Quarterly Revenue Growth

0.058

The market value of Merck Company is measured differently than its book value, which is the value of Merck that is recorded on the company's balance sheet. Investors also form their own opinion of Merck's value that differs from its market value or its book value, called intrinsic value, which is Merck's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Merck's market value can be influenced by many factors that don't directly affect Merck's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Merck's value and its price as these two are different measures arrived at by different means. Investors typically determine if Merck is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Merck's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Merck Total Assets from 2010 to 2024

Latest Merck's Total Assets Growth Pattern

Merck Total Assets Regression Statistics

Merck Total Assets History

Other Fundumenentals of Merck Company

Merck Total Assets component correlations

About Merck Financial Statements

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

Complementary Tools for Merck Stock analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY